Skip to main content
SpringerLink
Log in

Management of Patients with Prostate Cancer

  • Chapter
  • First Online:
Primer on Prostate Cancer

  • 701 Accesses

Abstract

Various new drugs and treatment techniques have become available in recent years for patients with prostate cancer. In addition, there is a growing realization that many patients with low-risk disease can be safely monitored initially with deferred treatment, if needed. These developments in therapies also coincide with advancements made in imaging technology, which may allow for better identification of those patients with potential life-threatening disease and other patients strictly in need of monitoring for indolent disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Heidenreich A, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.

    Google Scholar 

  2. Mottet N, Bellmunt J, Bolla M, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011;59:572–583.

    Google Scholar 

  3. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V; Panel Members. Prostate cancer: ESMO Consensus Conference guidelines 2012. Ann Oncol. 2013;24:1141–1162.

    Google Scholar 

  4. American Urological Association. Guideline for the management of clinically localized prostate cancer: 2007 update. www.auanet.org/common/pdf/education/clinical-guidance/Prostate-Cancer.pdf. Accessed July 18, 2013.

  5. Thompson IM, Valicenti R, Albertsen PC, et al. Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA guideline. www.auanet.org/common/pdf/education/clinical‑guidance/Radiation-After-Prostatectomy.pdf. Accessed July 18, 2013.

  6. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. J Urol. 2013;190:429–438.

    Google Scholar 

  7. Walsh PC, Lepor H. The role of radical prostatectomy in the management of prostatic cancer. Cancer. 1997;60(3 suppl):526–537.

    Google Scholar 

  8. Finkelstein J, Eckersberger E, Sadri H, Taneja SS, Lepor H, Djavan B. Open versus laparoscopic versus robot-assisted laparoscopic prostatectomy: the European and US experience. Rev Urol. 2010;12:35–43.

    Google Scholar 

  9. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol. 2002;167:1681–1686.

    Google Scholar 

  10. Mayo Clinic. Cryotherapy for prostate cancer. Risks. www.mayoclinic.com/health/cryotherapy‑for-prostate-cancer/MY01634/DSECTION=risks. Accessed July 18, 2013.

  11. Pommier P, Chabaud S, Lagrange JL, et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol. 2007;25:5366–5373.

    Google Scholar 

  12. Theodorescu D. Prostate cancer, clinical oncology. In: Schwab M, ed. Encyclopedic Reference of Cancer. Berlin, Germany: Springer-Verlag; 2001:720–727.

    Google Scholar 

  13. CyberKnife. Side Effects: Prostate. www.cyberknife.com/Content.aspx?id=5404. Accessed July 18, 2013.

  14. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293–297.

    Google Scholar 

  15. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461–3467.

    Google Scholar 

  16. Crook JM, O’Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367:895–903.

    Google Scholar 

  17. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756–1764.

    Google Scholar 

  18. de Bono JS, Logothetis CJ, Molina A, et al; for the COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.

    Google Scholar 

  19. Ryan CJ, Smith MR, de Bono JS, et al; for the COU-AA-302 Investigators. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138–148.

    Google Scholar 

  20. Trachtenberg J, Gittleman M, Steidle C, et al; Abarelix Study Group. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 2002;167:1670–1674.

    Google Scholar 

  21. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–1538.

    Google Scholar 

  22. Labrie F. Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol. 2011;8:73–85.

    Google Scholar 

  23. Scher HI, Fizazi K, Saad F, et al; for the AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–1197.

    Google Scholar 

  24. Sydes MR, James ND, Mason MD, et al. Flexible trial design in practice - dropping and adding arms in STAMPEDE: a multi-arm multi-stage randomised controlled trial. Trials. 2011;12(suppl 1):A3.

    Google Scholar 

  25. Medivation and Astellas announce the Phase 3 PREVAIL trial of enzalutamide meets both co-primary endpoints of overall survival and radiographic progression-free survival in chemotherapy-naive patients with advanced prostate cancer [press release October 22, 2013]. http://investors.medivation.com/releasedetail.cfm?ReleaseID=798880. Accessed October 24, 2013.

  26. Kantoff PW, Higano CS, Shore ND, et al; for the IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363:411–422.

    Google Scholar 

  27. Tannock IF, de Wit R, Berry WR, et al; for the TAX 3 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–1512.

    Google Scholar 

  28. de Bono JS, Oudard S, Ozguroglu M, et al; for the TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–1154.

    Google Scholar 

  29. Brady D, Parker CC, O’Sullivan JM. Bone-targeting radiopharmaceuticals including radium‑223. Cancer J. 2013;19:71–78.

    Google Scholar 

  30. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.

    Google Scholar 

  31. Roach M III, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585–591.

    Google Scholar 

  32. Bolla M, Van Tienhoven G, Warde P, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomized study. Lancet Oncol. 2010;11:1066–1073.

    Google Scholar 

  33. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol. 1997;15:1013–1021.

    Google Scholar 

  34. Widmark A, Klepp O, Solberg A, et al; for the Scandinavian Prostate Cancer Group Study 7/ the Swedish Association for Urological Oncology 3. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet. 2009;373:301–308.

    Google Scholar 

  35. Warde P, Mason M, Ding K, et al; for the NCIC CTG PR.3/MRC UK PR07 Investigators. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet. 2011;378:2104–2111.

    Google Scholar 

  36. Dearnaley DP, Sydes MR, Graham JD, et al; on behalf of the RT01 Collaborators. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8:475–487.

    Google Scholar 

  37. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol. 1999;17:2506–2513.

    Google Scholar 

  38. Berry W, Dakhil S, Modiano M, Gregurich M, Asmar L. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol. 2002;168:2439–2443.

    Google Scholar 

  39. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–1520.

    Google Scholar 

  40. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non‑castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:149–158.

    Google Scholar 

  41. Mayo Clinic. Prostate Cancer. www.mayoclinic.com/health/prostate-cancer-metastasis/AN02203. Accessed July 18, 2013.

  42. National Cancer Institute. Metastatic Cancer. www.cancer.gov/cancertopics/factsheet/Sites‑Types/metastatic. Accessed July 18, 2013.

  43. Saad F, Gleason DM, Murray R, et al; for the Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879–882.

    Google Scholar 

  44. Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377:813–822.

    Google Scholar 

  45. Porter AT, McEwan AJ. Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial. Semin Oncol. 1993;20:38–43.

    Google Scholar 

  46. Sartor O, Reid RH, Hoskin PJ, et al; Quadramet 424Sm10/11 Study Group. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63:940–945.

    Google Scholar 

  47. Dearnaley DP, Mason MD, Parmar MKB, Sanders K, Sydes MR. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials. Lancet Oncol. 2009;10:872–876.

    Google Scholar 

  48. National Comprehensive Cancer Center (NCCN). NCCN clinical practice guidelines in oncology (NCCN Guideline®): prostate cancer. www.nccn.org/professionals/physician_gls/pdf/prostate. pdf. Accessed July 18, 2013.

  49. Riccardi A, Grasso D, Danova M. Bisphosphonates in oncology: physiopathologic bases and clinical activity. Tumori. 2003;89:223–236.

    Google Scholar 

  50. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42’446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9:745–751.

    Google Scholar 

  51. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol. 2001;19:558–567.

    Google Scholar 

  52. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003;21:4277–4284.

    Google Scholar 

  53. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer. 2000;88(12 suppl):2934–2939.

    Google Scholar 

  54. QUADRAMETR® [package insert]. Langhorne, PA: EUSA Pharma (USA), Inc; 2009.

    Google Scholar 

  55. Wilt TJ, Brawer MK, Jones KM, et al; for the Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 2012;367:203–213.

    Google Scholar 

  56. Bill-Axelson A, Holmberg L, Ruutu M, et al; for the SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364:1708–1717

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Birmingham Oncology, Birmingham, UK

    Nicholas James

Authors
  1. Nicholas James
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas James .

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Healthcare

About this chapter

Cite this chapter

James, N. (2014). Management of Patients with Prostate Cancer. In: Primer on Prostate Cancer. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-82-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-82-5_3

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-907673-81-8

  • Online ISBN: 978-1-907673-82-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation